Business Standard

Sun Pharma gains ahead of Q2 results

The company may report 29% y-o-y growth in its consolidated net profit at Rs 772 crore in Q2.

Related News

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

The stock opened at Rs 700 and hit a high of Rs 714 on the NSE. A combined 684,427 shares have changed hands on the counter so far against an average 609,000 shares that were traded daily in past ten trading days.

According to an average analyst estimates, may report 29% year-on-year growth in its consolidated net profit at Rs 772 crore in the September 2012 quarter. The company had reported profit of Rs 598 crore in previous year quarter.

“Sun Pharma is likely to report strong revenue growth at 50% led by 18% growth in domestic formulations, 49% growth in Taro US revenues and niche launches in US viz. Lipodex and Stalevo. Operating margins are likely to expand by over 600 bps to 40%,” according to analyst at Emkay Global Financial Services.

Read more on:   
|
|

Sun Pharma gains ahead of Q2 results

The company may report 29% y-o-y growth in its consolidated net profit at Rs 772 crore in Q2.

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

Sun Pharmaceutical Industries is trading higher by 2% at Rs 712 in otherwise subdued market ahead of September quarter earnings later today.

The stock opened at Rs 700 and hit a high of Rs 714 on the NSE. A combined 684,427 shares have changed hands on the counter so far against an average 609,000 shares that were traded daily in past ten trading days.

According to an average analyst estimates, may report 29% year-on-year growth in its consolidated net profit at Rs 772 crore in the September 2012 quarter. The company had reported profit of Rs 598 crore in previous year quarter.

“Sun Pharma is likely to report strong revenue growth at 50% led by 18% growth in domestic formulations, 49% growth in Taro US revenues and niche launches in US viz. Lipodex and Stalevo. Operating margins are likely to expand by over 600 bps to 40%,” according to analyst at Emkay Global Financial Services.

image

Read More

BSE launches carbon index

Premier bourse BSE, in collaboration with the UK government, today launched BSE Carbonex, the first-of-its-kind index in India or any emerging market ...

Recommended for you

Advertisements

Quick Links

Market News

Sugar sheds 0.44% on higher supply

However, scattered demand from bulk consumers due to summer season, limits the fall

Mustardseed futures weaken on profit-booking, low demand

May, June contracts shed 1% as traders exit on lower offtake in spot market

Kaveri Seed drops as RBI caps further FII investment

Shareholding by FIIs/FPIs has reached the trigger limit

Sebi-FMC merger to delay exchange IPOs

Says issues need to be sorted out before exchanges are given a green signal to list

Markets pare gains; HDFC Bank, Bharti Airtel dip over 1%

At 12.15 PM, the 30-share Sensex is down 36 points at 27,141 and the 50-share Nifty has lost 7 points at 8,207

 

Back to Top